These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 33763947)
1. Natural history of hepatitis C virus infection in a large national seroconversion cohort in the direct-acting antiviral agent era: Results from ERCHIVES. Butt AA; Yan P; J Viral Hepat; 2021 Jun; 28(6):916-924. PubMed ID: 33763947 [TBL] [Abstract][Full Text] [Related]
2. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544 [TBL] [Abstract][Full Text] [Related]
3. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents. Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690 [TBL] [Abstract][Full Text] [Related]
4. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL; Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748 [TBL] [Abstract][Full Text] [Related]
5. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis. Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA; Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891 [TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study. Choi GH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Jang JW; Ki M; Choi HY; Baik D; Jeong SH World J Gastroenterol; 2022 Aug; 28(30):4182-4200. PubMed ID: 36157119 [TBL] [Abstract][Full Text] [Related]
7. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Li DK; Ren Y; Fierer DS; Rutledge S; Shaikh OS; Lo Re V; Simon T; Abou-Samra AB; Chung RT; Butt AA Hepatology; 2018 Jun; 67(6):2244-2253. PubMed ID: 29205416 [TBL] [Abstract][Full Text] [Related]
8. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C; J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES). Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808 [TBL] [Abstract][Full Text] [Related]
10. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV). Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565 [TBL] [Abstract][Full Text] [Related]
11. DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C. Zhu X; Jia L; Yue M; Zhang A; Xia X; Yu R; Chen H; Huang P Sci Rep; 2024 Oct; 14(1):23760. PubMed ID: 39390065 [TBL] [Abstract][Full Text] [Related]
12. Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. Mendizabal M; Piñero F; Ridruejo E; Herz Wolff F; Anders M; Reggiardo V; Ameigeiras B; Palazzo A; Alonso C; Schinoni MI; Videla Zuain MG; Tanno F; Figueroa S; Santos L; Peralta M; Soza A; Vistarini C; Adrover R; Fernández N; Perez D; Hernández N; Estepo C; Bruno A; Descalzi V; Sixto M; Borzi S; Cocozzella D; Zerega A; de Araujo A; Varón A; Rubinstein F; Cheinquer H; Silva M; ; Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2554-2563.e3. PubMed ID: 32113892 [TBL] [Abstract][Full Text] [Related]
13. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765 [TBL] [Abstract][Full Text] [Related]
14. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V; Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836 [TBL] [Abstract][Full Text] [Related]
15. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E; Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138 [TBL] [Abstract][Full Text] [Related]
16. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959 [TBL] [Abstract][Full Text] [Related]
17. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ Aliment Pharmacol Ther; 2020 Jan; 51(1):34-52. PubMed ID: 31808566 [TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841 [TBL] [Abstract][Full Text] [Related]
19. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807 [TBL] [Abstract][Full Text] [Related]
20. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]